Idiopathic pulmonary fibrosis (IPF) is an orphan disease affecting approximately 50,000 people in the United States. It is characterized by an irreversible loss of lung function, leading to high morbidity and mortality; most patients die within three to five years following diagnosis. Pirfenidone (Roche’s Esbriet) and nintedanib (Boehringer Ingelheim’s Ofev) are the only two drugs approved for adults with mild to moderate IPF. Other than these two disease-modifying therapies (DMTs), physicians also prescribe other off-label medications (e.g., corticosteroids and anticoagulants) to treat IPF patients when the risk/benefit profile does not warrant treatment with pirfenidone or nintedanib, or when patients cannot receive reimbursement or afford the coinsurance for these two DMTs. Our Treatment Algorithms study provides national patient-level claims data to explore the use of key therapies in both newly diagnosed and recently treated patients, providing insight into the current treatment landscape for IPF.
- What patient share do key therapies and brands garner by line of treatment in newly diagnosed IPF patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed IPF patients?
- What proportion of IPF patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of IPF patients are treated with monotherapy versus combination therapy? What are the most widely used combination therapies?
- What are the product-level compliance and persistency rates among drug-treated patients with IPF ?
Treatment Algorithms: Claims Data Analysis provides detailed analysis of brand usage across different lines of therapy using real-world data patient-level claims data so you can accurately assess your source of business and quantify areas of opportunity for increasing your brand share.